Switch theme
Sign up to access all valuation multiples
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
2010
n/a
LTM Revenue n/a
LTM EBITDA n/a
$792M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhejiang Ausun has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Zhejiang Ausun achieved revenue of $113M and an EBITDA of $46.8M.
Zhejiang Ausun expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhejiang Ausun valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $113M | n/a | XXX | XXX | XXX |
| Gross Profit | $43.0M | $54.3M | XXX | XXX | XXX |
| Gross Margin | 38% | NaN% | XXX | XXX | XXX |
| EBITDA | $46.8M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 42% | NaN% | XXX | XXX | XXX |
| Net Profit | $20.1M | $32.4M | XXX | XXX | XXX |
| Net Margin | 18% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zhejiang Ausun's stock price is CNY 8 (or $1).
Zhejiang Ausun has current market cap of CNY 6.5B (or $891M), and EV of CNY 5.7B (or $792M).
See Zhejiang Ausun trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $792M | $891M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zhejiang Ausun has market cap of $891M and EV of $792M.
Zhejiang Ausun's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Zhejiang Ausun's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zhejiang Ausun and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $792M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZhejiang Ausun's NTM/LTM revenue growth is n/a
Zhejiang Ausun's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Zhejiang Ausun's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zhejiang Ausun's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zhejiang Ausun and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 23% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Ausun acquired XXX companies to date.
Last acquisition by Zhejiang Ausun was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhejiang Ausun acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zhejiang Ausun founded? | Zhejiang Ausun was founded in 2010. |
| Where is Zhejiang Ausun headquartered? | Zhejiang Ausun is headquartered in China. |
| Is Zhejiang Ausun publicy listed? | Yes, Zhejiang Ausun is a public company listed on SHG. |
| What is the stock symbol of Zhejiang Ausun? | Zhejiang Ausun trades under 603229 ticker. |
| When did Zhejiang Ausun go public? | Zhejiang Ausun went public in 2017. |
| Who are competitors of Zhejiang Ausun? | Similar companies to Zhejiang Ausun include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zhejiang Ausun? | Zhejiang Ausun's current market cap is $891M |
| Is Zhejiang Ausun profitable? | Yes, Zhejiang Ausun is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
